Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abacavir, Amprenavir, and Efavirenz in PI-Experienced HIV-1 Patients
NCT00002213Phase 2Completed
- Sponsor
- GSK
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abacavir, amprenavir and efavirenz in human immunodeficiency virus infection (HIV), sponsored by GSK. Primary endpoints: Plasma HIV-1 RNA levels at 48 weeks and Safety and tolerability at 48 weeks. Status: completed.
02
Drugs
abacaviramprenavirefavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002213.